Teva Pharmaceutical Industries Ltd (TEVA)

pos +0.00
Today's Range: 56.84 - 57.80 | TEVA Avg Daily Volume: 4,148,500
Last Update: 01/30/15 - 4:05 PM EST
Volume: 0
YTD Performance: -1.13%
Open: $0.00
Previous Close: $57.56
52 Week Range: $43.22 - $61.90
Oustanding Shares: 855,000,000
Market Cap: 49,213,800,000
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 11 11
Moderate Buy 1 1 1 0
Hold 10 10 10 10
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.95 1.95 1.95 1.95
Latest Dividend: 0.27
Latest Dividend Yield: 2.00%
Dividend Ex-Date: 11/13/14
Price Earnings Ratio: 38.63
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
38.63 17.90 25.69
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.69% 24.75% 26.55%
Revenue 0.00 0.26 0.08
Net Income -34.40 -0.62 -0.28
EPS -33.60 -0.60 -0.26
Earnings for TEVA:
Revenue 20.31B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $1.30 $1.26 $5.06 $5.16
Number of Analysts 11 5 14 14
High Estimate $1.33 $1.41 $5.10 $5.30
Low Estimate $1.22 $1.17 $4.99 $5.05
Prior Year $1.42 $1.22 $5.01 $5.06
Growth Rate (Year over Year) -8.77% 3.61% 1.04% 1.90%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

Take a Look at Teva Real Money Pro($)

We like new initiatives and see solid upside potential.
Dec 12, 2014 | 8:15 AM EST
TEVA was upgraded from Neutral to Buy, Sterne Agee said. $65 price target. Estimates also upped, given the company's new guidance. ...

Merger Mania Benefits Mylan Real Money Pro($)

Whether it's acquiring or the acquired, Mylan is building shareholder value.
Investing during a mid-term election can offer large returns.
Aug 04, 2014 | 7:56 AM EDT
TEVA price target raised from $50 to $54, UBS said. Neutral rating. Estimate also raised due to higher base sales.

Off the Charts Real Money Pro($)

We raised our stops on Teva and added Staples to the long ideas table.
It is preserving its Copaxone franchise, and the executive changes are good news.

Waiting for the Fed Real Money Pro($)

In a flattish market, transports are strong on FedEx's earnings, and small-caps are underperforming.
Conflicting technical patterns suggest one is healthy and the other could be under the weather.

Teva Is a Trade Opportunity Real Money Pro($)

 Stocks with good fundamentals are getting some respect.

Columnist Conversations

It's been a while since I have shown this chart. For the last 2 years the yields on the Five Year Note have tr...
Ugly end to a challenging week as stocks post around three percent declines for the opening month of 2015. Oil...
I have scaled further into a TLT short - scaling all the way up to $138.35 this morning. And I have scaled int...
Market slightly down despite the boost Amazon (AMZN) is giving the NASDAQ. Biotech also continues to be a stro...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.